Effects of a 6-month self-rehabilitation programme in addition to botulinum toxin injections and conventional physiotherapy on limitations of patients with spastic hemiparesis following stroke (ADJU-TOX): protocol study for a randomised controlled, investigator blinded study

Celine Bonnyaud, Philippe Gallien, Pierre Decavel, Philippe Marque, Claire Aymard, Frédéric Pellas, Marie-Eve Isner, François Constant Boyer, François Muller, Jean-Christophe Daviet, Patrick Dehail, Brigitte Perrouin-Verbe, Nicolas Bayle, Emmanuel Coudeyre, Dominic Perennou, Isabelle Laffont, Jacques Ropers, Nabila-Yasmine Domingo-Saidji, Djamel Bensmail, Nicolas Roche, ADJU-TOX Study Group, Bernard Parratte, Théo Maulet, Philippe Aegerter, Priyanka Velou, Julia San, Yassine Omri, Myriem Carrier, Celine Bonnyaud, Philippe Gallien, Pierre Decavel, Philippe Marque, Claire Aymard, Frédéric Pellas, Marie-Eve Isner, François Constant Boyer, François Muller, Jean-Christophe Daviet, Patrick Dehail, Brigitte Perrouin-Verbe, Nicolas Bayle, Emmanuel Coudeyre, Dominic Perennou, Isabelle Laffont, Jacques Ropers, Nabila-Yasmine Domingo-Saidji, Djamel Bensmail, Nicolas Roche, ADJU-TOX Study Group, Bernard Parratte, Théo Maulet, Philippe Aegerter, Priyanka Velou, Julia San, Yassine Omri, Myriem Carrier

Abstract

Introduction: Home-based self-rehabilitation programmes combined with botulinum toxin injections (BTIs) appear to be a relevant approach to increase the recommended intensive rehabilitation of patients with spasticity following a stroke. The literature highlights a lack of evidence of beneficial effects of this adjuvant therapy to reduce limitations of patients with stroke. The aim of this study is to assess the effects of a 6-month self-rehabilitation programme in adjunction to BTI, in comparison with BTI alone, to reduce limitations of patients with spasticity following a stroke.

Methods and analysis: 220 chronic patients will participate to this multicentre, prospective, randomised, controlled, assessor blinded study. All patients will benefit from two successive BTI (3 months apart), and patients randomised in the self-rehabilitation group will perform in adjunction 6 months of self-rehabilitation at home. All patients continue their conventional physiotherapy. The main outcome is the primary treatment goal (PTG), which will be determined jointly by the patient and the medical doctor using Goal Attainment Scaling. Impairments and functions, quality of life, mood and fatigue will be assessed. Botulinum toxin will be injected into the relevant muscles according to the PTG. Patients in the self-rehab group will be taught the self-rehabilitation programme involving respectively 10 min of stretching, 10 min of strengthening and 10 min of task-oriented exercises, corresponding to their PTG. Compliance to the self-rehabilitation programme will be monitored.

Ethics and dissemination: Patients will sign written informed consent. Ethical approval was obtained from ethics committee. The results will be disseminated in a peer-reviewed journal and presented at international congresses. The results will also be disseminated to patients.

Trial registration number: NCT02944929.

Keywords: Botulinum Toxin; Goal Attainment Scaling; Self-rehabilitation; Spasticity Management; Stroke.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Path of the 6 min walk test with obstacles and no obstacles.
Figure 2
Figure 2
Study’s flow chart.

References

    1. Fery-Lemonnier E. La prévention et la prise en charge des accidents vasculaires cérébraux en France Synthèse du Rapp à Madame la Minist la santé des Sport, 2009.
    1. Kelly-Hayes M, Beiser A, Kase CS, et al. . The influence of gender and age on disability following ischemic stroke: the Framingham study. J Stroke Cerebrovasc Dis 2003;12:119–26. 10.1016/S1052-3057(03)00042-9
    1. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. . Long-term disability after first-ever stroke and related prognostic factors in the Perth Community Stroke Study, 1989-1990. Stroke 2002;33:1034–40. 10.1161/01.STR.0000012515.66889.24
    1. Twitchell TE. The restoration of motor function following hemiplegia in man. Brain 1951;74:443–80. 10.1093/brain/74.4.443
    1. Bhakta BB, Cozens JA, Chamberlain MA, et al. . Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217–21. 10.1136/jnnp.69.2.217
    1. Barnes. M. Upper motor neurone syndrome and spasticity. Clinical management and neurophysiology. Cambridge, 2008.
    1. Perry J, Garrett M, Gronley JK, et al. . Classification of walking handicap in the stroke population. Stroke 1995;26:982–9. 10.1161/01.STR.26.6.982
    1. Schmid A, Duncan PW, Studenski S, et al. . Improvements in speed-based gait classifications are meaningful. Stroke 2007;38:2096–100. 10.1161/STROKEAHA.106.475921
    1. Olney SJ, Griffin MP, McBride ID. Temporal, kinematic, and kinetic variables related to gait speed in subjects with hemiplegia: a regression approach. Phys Ther 1994;74:872–85. 10.1093/ptj/74.9.872
    1. Olney SJ, Richards C. Hemiparetic gait following stroke. Part I: Characteristics. Gait Posture 1996;4:136–48. 10.1016/0966-6362(96)01063-6
    1. Kerrigan DC, Gronley J, Perry J. Stiff-legged gait in spastic paresis. A study of quadriceps and hamstrings muscle activity. Am J Phys Med Rehabil 1991;70:294–300. 10.1097/00002060-199112000-00003
    1. Burbaud P, Wiart L, Dubos JL, et al. . A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265–9. 10.1136/jnnp.61.3.265
    1. Ferrarello F, Baccini M, Rinaldi LA, et al. . Efficacy of physiotherapy interventions late after stroke: a meta-analysis. J Neurol Neurosurg Psychiatry 2011;82:136–43. 10.1136/jnnp.2009.196428
    1. Pollock A, Farmer SE, Brady MC, et al. . Interventions for improving upper limb function after stroke. Cochrane database Syst Rev 2014;11:CD010820.
    1. Kollen BJ, Lennon S, Lyons B, et al. . The effectiveness of the Bobath concept in stroke rehabilitation: what is the evidence? Stroke 2009;40:e89–97. 10.1161/STROKEAHA.108.533828
    1. Kwakkel G, Kollen BJ, Krebs HI. Effects of robot-assisted therapy on upper limb recovery after stroke: a systematic review. Neurorehabil Neural Repair 2008;22:111–21. 10.1177/1545968307305457
    1. Rodgers H, Mackintosh J, Price C, et al. . Does an early increased-intensity interdisciplinary upper limb therapy programme following acute stroke improve outcome? Clin Rehabil 2003;17:579–89. 10.1191/0269215503cr652oa
    1. Glasgow Augmented Physiotherapy Study (GAPS) group. Can augmented physiotherapy input enhance recovery of mobility after stroke? A randomized controlled trial. Clin Rehabil 2004;18:529–37. 10.1191/0269215504cr768oa
    1. Langhorne P, Coupar F, Pollock A. Motor recovery after stroke: a systematic review. Lancet Neurol 2009;8:741–54. 10.1016/S1474-4422(09)70150-4
    1. Wevers L, van de Port I, Vermue M, et al. . Effects of task-oriented circuit class training on walking competency after stroke: a systematic review. Stroke 2009;40:2450–9. 10.1161/STROKEAHA.108.541946
    1. French B, Leathley M, Sutton C, et al. . A systematic review of repetitive functioal task practice with modelling of resource use, cost and effectiveness. Health Technol Assess 2008;12:1–140.
    1. van de Port IG, Wevers LE, Lindeman E, et al. . Effects of circuit training as alternative to usual physiotherapy after stroke: randomised controlled trial. BMJ 2012;344:e2672 10.1136/bmj.e2672
    1. Green J, Forster A, Bogle S, et al. . Physiotherapy for patients with mobility problems more than 1 year after stroke: a randomised controlled trial. Lancet 2002;359:199–203. 10.1016/S0140-6736(02)07443-3
    1. Tosun J. Etude de l’autonomie des patients hémiparétiques au stade chronique d’un accident vasculaire cérébral en médecine générale, 2010.
    1. Gordon NF, Gulanick M, Costa F, et al. . Physical activity and exercise recommendations for stroke survivors: an american heart association scientific statement from the council on clinical cardiology, subcommittee on exercise, cardiac rehabilitation, and prevention; the council on cardiovascula. Circulation 2004;109:2031–41.
    1. Caty GD, Detrembleur C, Bleyenheuft C, et al. . Effect of simultaneous botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait. Stroke 2008;39:2803–8. 10.1161/STROKEAHA.108.516153
    1. Bensmail D, Robertson JV, Fermanian C, et al. . Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements. Neurorehabil Neural Repair 2010;24:273–81. 10.1177/1545968309347682
    1. Pradon D, Hutin E, Khadir S, et al. . A pilot study to investigate the combined use of Botulinum toxin type-a and ankle foot orthosis for the treatment of spastic foot in chronic hemiplegic patients. Clin Biomech 2011;26:867–72. 10.1016/j.clinbiomech.2011.04.003
    1. Foley N, Pereira S, Salter K, et al. . Treatment with botulinum toxin improves upper-extremity function post stroke: a systematic review and meta-analysis. Arch Phys Med Rehabil 2013;94:977–89. 10.1016/j.apmr.2012.12.006
    1. Sheean G, Lannin NA, Turner-Stokes L, et al. . Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol 2010;17(Suppl 2):74–93. 10.1111/j.1468-1331.2010.03129.x
    1. Pittock SJ, Moore AP, Hardiman O, et al. . A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289–300. 10.1159/000069495
    1. Mancini F, Sandrini G, Moglia A, et al. . A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26:26–31. 10.1007/s10072-005-0378-9
    1. Robertson JV, Pradon D, Bensmail D, et al. . Relevance of botulinum toxin injection and nerve block of rectus femoris to kinematic and functional parameters of stiff knee gait in hemiplegic adults. Gait Posture 2009;29:108–12. 10.1016/j.gaitpost.2008.07.005
    1. Ashford S, Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin. Physiother Res Int 2006;11:24–34. 10.1002/pri.36
    1. Turner-Stokes L, Baguley IJ, De Graaff S, et al. . Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial. J Rehabil Med 2010;42:81–9. 10.2340/16501977-0474
    1. Elovic EP, Brashear A, Kaelin D, et al. . Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008;89:799–806. 10.1016/j.apmr.2008.01.007
    1. Gordon MF, Brashear A, Elovic E, et al. . Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004;63:1971–3. 10.1212/01.WNL.0000144349.95487.91
    1. Roche N, Geiger M, Marcieca P, et al. . Improvement in the Gait Pattern of Chronic Stroke Patients following Repetitive Multifocal Botulinum Toxin Injections: An Observational Study. Int J Phys Med Rehabil 2015;3:521–4.
    1. Sun SF, Hsu CW, Sun HP, et al. . Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study. Neurorehabil Neural Repair 2010;24:34–41. 10.1177/1545968309341060
    1. Roche N, Zory R, Sauthier A, et al. . Effect of rehabilitation and botulinum toxin injection on gait in chronic stroke patients: a randomized controlled study. J Rehabil Med 2015;47:31–7. 10.2340/16501977-1887
    1. Moore EJ, Banky M, Olver J, et al. . The effectiveness of therapy on outcome following (BoNT-A) injection for focal spasticity in adults with neurological conditions: A systematic review. Brain Inj 2015;29:676–87. 10.3109/02699052.2015.1004749
    1. Mills PB, Finlayson H, Sudol M, et al. . Systematic review of adjunct therapies to improve outcomes following botulinum toxin injection for treatment of limb spasticity. Clin Rehabil 2016;30:537–48. 10.1177/0269215515593783
    1. Goldstein M, Barnett HJM. World Health Organization. Stroke–1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989;20:1407–31.
    1. Wissel J, Ward AB, Erztgaard P, et al. . European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41:13–25. 10.2340/16501977-0303
    1. Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J 1968;4:443–53. 10.1007/BF01530764
    1. Richardson D, Sheean G, Werring D, et al. . Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499–506. 10.1136/jnnp.69.4.499
    1. Wissel J, Müller J, Dressnandt J, et al. . Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44–9. 10.1016/S0885-3924(00)00146-9
    1. Slawinski J, Pradon D, Bensmail D, et al. . Energy cost of obstacle crossing in stroke patients. Am J Phys Med Rehabil 2014;93:1044–50. 10.1097/PHM.0000000000000122
    1. Turner-Stokes L, Fheodoroff K, Jacinto J, et al. . Results from the Upper Limb International Spasticity Study-II (ULISII):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open 2013;3:e002771 10.1136/bmjopen-2013-002771
    1. Demetrios M, Gorelik A, Louie J, et al. . Outcomes of ambulatory rehabilitation programmes following botulinum toxin for spasticity in adults with stroke. J Rehabil Med 2014;46:730–7. 10.2340/16501977-1842
    1. Julious SA, McIntyre NE. Sample sizes for trials involving multiple correlated must-win comparisons. Pharm Stat 2012;11:177–85. 10.1002/pst.515
    1. Little R, Rubin D. Statistical analysis with missing data. New York: John Wiley, 1987.
    1. Carda S, Invernizzi M, Baricich A, et al. . Casting, taping or stretching after botulinum toxin type A for spastic equinus foot: a single-blind randomized trial on adult stroke patients. Clin Rehabil 2011;25:1119–27. 10.1177/0269215511405080
    1. Weber DJ, Skidmore ER, Niyonkuru C, et al. . Cyclic functional electrical stimulation does not enhance gains in hand grasp function when used as an adjunct to onabotulinumtoxinA and task practice therapy: a single-blind, randomized controlled pilot study. Arch Phys Med Rehabil 2010;91:679–86. 10.1016/j.apmr.2010.01.010
    1. Demetrios M, Khan F, Turner-Stokes L, et al. . Multidisciplinary rehabilitation following botulinum toxin and other focal intramuscular treatment for post-stroke spasticity. Cochrane Database Syst Rev 2013;6:CD009689 10.1002/14651858.CD009689.pub2

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner